A Phase 1 interventional study of MLN2480 and MLN0128 in Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
The drug being tested in this study is called MLN2480 (TAK-580). MLN2480 was tested to evaluate side effects and determine the maximum tolerated dose (MTD) and recommended dose for future studies when administered in combination with five other medications. This study was to assess the safety of MLN2480 as well as how it is processed by the body in participants with solid nonhematologic malignancies who have failed standard therapies.
The study was to be conducted in two phases, the dose escalation phase and the dose expansion phase. A total of 71 participants were enrolled in the escalation phase. Participants in this phase were assigned to one of the five treatment groups:
Once the MTD for each combination treatment arm was established in the escalation phase, one or more of the combination treatments will be selected for the expansion phase. A total of 10 participants were enrolled in the expansion phase.
This multi-centre trial was be conducted worldwide. The overall time to participate in this study is approximately 14 months. Participants made multiple visits to the clinic including an end of study visit 30 days after last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Treatment Arms:
Additional inclusion criteria for arm 3 expansion only (MLN2480 + paclitaxel):
a. Participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2 or BRAF non-V600 mutation-positive non-small cell lung cancer (NSCLC) who have received a minimum of 1 but not more than 2 prior cytotoxic-approved regimens.
Additional inclusion criteria for arms 4 and 5 expansion only (MLN2480 + cetuximab; MLN2480 + irinotecan):
Exclusion Criteria:
All treatment arms:
Additional exclusion criteria for arms 3, 5, and 6 expansion only (MLN2480 + paclitaxel; MLN2480 + irinotecan; MLN2480 monotherapy):
a. Prior treatment with rapidly accelerated fibrosarcoma (RAF), extracellular signal-regulated kinases (MEK), or other inhibitors of the mitogen-activated protein kinase (MAPK) pathway.
Additional exclusion criteria for arm 2 only (MLN2480 + alisertib):
a. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe .
Additional exclusion criteria for arm 3 only (MLN2480 + paclitaxel):
a. Known to paclitaxel, or its components or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil).
Additional exclusion criteria for arm 5 only (MLN2480 + irinotecan):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
Drug: MLN2480 · Drug: MLN0128
Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
Drug: MLN2480 · Drug: Alisertib
Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m\^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m\^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
Drug: MLN2480 · Drug: Paclitaxel
Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m\^2 (cycle 1 Day 1), then at 250 mg/m\^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
Drug: MLN2480 · Drug: Cetuximab
Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m\^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
Drug: MLN2480 · Drug: Irinotecan
Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
Drug: MLN2480
MLN2480 tablets.
Also known as: TAK-580
MLN0128 capsules.
Alisertib tablets.
Paclitaxel IV infusion.
Cetuximab IV infusion.
Irinotecan IV infusion.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE means any untoward medical occurrence that at any dose results in death, is life-threatening, requires in patient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)
Number of Participants With Dose-Limiting Toxicities (DLTs)
DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and included: any drug-related hematologic toxicity ≥Grade 4 with the exception of Grade 4 neutropenia \<7 days duration; Grade 3 or 4 neutropenia with fever \>38.5 degrees Celsius and/or infection or neutropenia requiring colony-stimulating factor OR non-hematologic DLTs that were any Grade 3, 4, or 5 toxicity with the following exceptions: Grade 3 nausea, vomiting, diarrhea, and dehydration occurring in a setting of inadequate treatment; inadequately treated hypersensitivity reactions; Grade 3 elevated transaminases or urine electrolyte abnormality ≤1 week in duration; Grade 3 serum electrolyte abnormality ≤72 hours in duration. DLTs also included: drug-related adverse experience that lead to a dose modification; unresolved drug-related toxicity resulted in delay in initiation of Cycle 2.
Time frame: From Day 1, Cycle 1 through 30 days after the last dose in Cycle 1 (up to 8 weeks)
Maximum Tolerated Dose (MTD) for MLN2480
Time frame: Day 1, Cycle 1 up to 28 days
Recommended Phase 2 Dose (RP2D) of MLN2480
Time frame: Day 1, Cycle 1 up to 28 days
Cmax : Maximum Observed Plasma Concentration for MLN2480
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for MLN0128
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for Alisertib
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN2480
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN2480
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN0128
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for Paclitaxel
Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
AUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel
Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Terminal Elimination Half-life (T1/2) for Paclitaxel
Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose
Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Time frame: Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Up to 13 months)
Duration of Response
Duration of Response (DOR) was defined as the time in months from the first documented CR or PR per RECIST v. 1.1 to disease recurrence or disease progression (PD) whichever occurs first.
Time frame: From first documented response until disease progression (Up to 13 months)
Time to Response
Time to response was defined as the time in months from the date of first dose of study treatment to the date of the first documentation of a PR or better response.
Time frame: From date of enrollment to the date of the first documentation of a confirmed response (Up to 13 months)
Progression Free Survival (PFS)
PFS is defined as the time in months from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Approximately up to 13 months)
Participants took part in the study at 14 investigative sites in the United States, France, Spain, and United Kingdom from 14 September 2016 to 02 July 2018.
| Milestone | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 7 | 3 | 8 | 4 | 3 | 4 | 6 | 8 | 6 | 7 | 1 | 7 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 7 | 3 | 8 | 4 | 3 | 4 | 6 | 8 | 6 | 7 | 1 | 7 | 10 |
| Withdrew: Progressive disease | 1 | 3 | 4 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 1 | 3 | 3 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 2 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE means any untoward medical occurrence that at any dose results in death, is life-threatening, requires in patient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
| Participants | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 4 | 3 | 7 | 3 | 8 | 4 | 3 | 4 | 6 | 8 | 6 | 7 | 1 | 7 | 10 |
| SAEs | 2 | 1 | 5 | 1 | 3 | 1 | 1 | 2 | 3 | 4 | 2 | 3 | 0 | 4 | 7 |
DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and included: any drug-related hematologic toxicity ≥Grade 4 with the exception of Grade 4 neutropenia \<7 days duration; Grade 3 or 4 neutropenia with fever \>38.5 degrees Celsius and/or infection or neutropenia requiring colony-stimulating factor OR non-hematologic DLTs that were any Grade 3, 4, or 5 toxicity with the following exceptions: Grade 3 nausea, vomiting, diarrhea, and dehydration occurring in a setting of inadequate treatment; inadequately treated hypersensitivity reactions; Grade 3 elevated transaminases or urine electrolyte abnormality ≤1 week in duration; Grade 3 serum electrolyte abnormality ≤72 hours in duration. DLTs also included: drug-related adverse experience that lead to a dose modification; unresolved drug-related toxicity resulted in delay in initiation of Cycle 2.
| Participants | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| mg | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) for MLN2480 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 600 | NA | NA | NA | NA | NA |
| mg | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recommended Phase 2 Dose (RP2D) of MLN2480 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 600 | NA | NA | NA | NA | NA |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
| percentage of participants | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 17 (1 to 64) | 75 (19 to 99) | 0 (0 to 0) | 0 (0 to 0) | 40 (5 to 85) | 17 (1 to 64) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 38 (9 to 76) |
Duration of Response (DOR) was defined as the time in months from the first documented CR or PR per RECIST v. 1.1 to disease recurrence or disease progression (PD) whichever occurs first.
| months | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | — | — | — | — | NA (NA to NA) | 3.7 (1.0 to 5.8) | — | — | 6.5 (1.7 to 11.2) | 3.5 (NA to NA) | — | — | — | — | 11.5 (NA to NA) |
Time to response was defined as the time in months from the date of first dose of study treatment to the date of the first documentation of a PR or better response.
| months | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Response | — | — | — | — | 4.2 (NA to NA) | 3.7 (2.3 to 3.7) | — | — | 2.7 (1.9 to 3.6) | 1.8 (NA to NA) | — | — | — | — | 1.9 (1.9 to 2.0) |
PFS is defined as the time in months from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 0.5 (NA to NA) | 1.9 (1.1 to 16.6) | 3.7 (0.4 to 4.6) | 1.9 (1.7 to 4.6) | 9.5 (0.6 to 9.7) | 5.3 (1.3 to 9.5) | 5.5 (1.5 to 7.4) | 2.9 (1.9 to 3.7) | 7.6 (3.6 to 14.7) | 3.3 (1.8 to NA) | 2.2 (1.3 to NA) | 1.7 (1.0 to 5.4) | 3.6 (NA to NA) | 4.7 (1.8 to NA) | 5.7 (2.2 to 13.3) |
Collected over AEs were recorded from the first dose of study drug through 30 days after the last dose of study drug or the start of subsequent antineoplastic therapy, whichever occurred first. SAEs were collected from the signing of Informed Consent through 30 days after the last dose of study drug (Up to 13 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MLN2480 100 mg + MLN0128 2 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| MLN2480 100 mg + Alisertib 30 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| MLN2480 160 mg + Alisertib 30 mg | 2/7 (28.6%) | 5/7 (71.4%) | 7/7 (100%) |
| MLN2480 200 mg + Alisertib 30 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| MLN2480 100 mg + Alisertib 40 mg | 1/8 (12.5%) | 3/8 (37.5%) | 8/8 (100%) |
| MLN2480 100 mg + Paclitaxel 80 mg/m^2 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| MLN2480 160 mg + Paclitaxel 80 mg/m^2 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| MLN2480 200 mg + Paclitaxel 80 mg/m^2 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| MLN2480 400 mg + Paclitaxel 80 mg/m^2 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| MLN2480 600 mg + Paclitaxel 80 mg/m^2 | 0/8 (0%) | 4/8 (50%) | 8/8 (100%) |
| MLN2480 400 mg + Cetuximab 250 mg/m^2 | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| MLN2480 600 mg + Cetuximab 250 mg/m^2 | 2/7 (28.6%) | 3/7 (42.9%) | 7/7 (100%) |
| ML2480 300 mg + Irinotecan 180 mg/m^2 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| ML2480 400 mg + Irinotecan 180 mg/m^2 | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | 2/10 (20%) | 7/10 (70%) | 10/10 (100%) |
| Event | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/7 | 1/3 | 0/8 | 1/4 | 0/3 | 1/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 1/7 | 0/10 |
| NauseaGastrointestinal disorders | 0/4 | 0/3 | 0/7 | 1/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 1/6 | 0/7 | 0/1 | 2/7 | 0/10 |
| VomitingGastrointestinal disorders | 0/4 | 0/3 | 0/7 | 1/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 1/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| Post-tussive vomitingGastrointestinal disorders | 0/4 | 0/3 | 0/7 | 1/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| Small intestinal obstructionGastrointestinal disorders | 0/4 | 1/3 | 0/7 | 0/3 | 0/8 | 0/4 | 0/3 | 0/4 | 1/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| PneumoniaInfections and infestations | 0/4 | 0/3 | 1/7 | 1/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 1/10 |
| Splenic haemorrhageBlood and lymphatic system disorders | 0/4 | 0/3 | 0/7 | 0/3 | 0/8 | 0/4 | 1/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/7 | 0/3 | 1/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 2/7 | 0/10 |
| Urinary tract infectionInfections and infestations | 1/4 | 0/3 | 0/7 | 0/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/7 | 0/3 | 0/8 | 0/4 | 0/3 | 1/4 | 0/6 | 0/8 | 0/6 | 0/7 | 0/1 | 0/7 | 0/10 |
| Event | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HypophosphataemiaMetabolism and nutrition disorders | 1/4 | 0/3 | 6/7 | 2/3 | 1/8 | 0/4 | 3/3 | 2/4 | 4/6 | 7/8 | 6/6 | 4/7 | 0/1 | 5/7 | 6/10 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 1/3 | 5/7 | 1/3 | 5/8 | 2/4 | 2/3 | 1/4 | 2/6 | 1/8 | 0/6 | 1/7 | 1/1 | 2/7 | 5/10 |
| NauseaGastrointestinal disorders | 2/4 | 1/3 | 3/7 | 1/3 | 3/8 | 3/4 | 1/3 | 3/4 | 3/6 | 1/8 | 0/6 | 2/7 | 1/1 | 4/7 | 6/10 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/3 | 0/7 | 0/3 | 1/8 | 1/4 | 0/3 | 1/4 | 3/6 | 1/8 | 1/6 | 2/7 | 1/1 | 2/7 | 2/10 |
| FatigueGeneral disorders | 3/4 | 3/3 | 5/7 | 1/3 | 5/8 | 2/4 | 2/3 | 1/4 | 3/6 | 3/8 | 0/6 | 2/7 | 1/1 | 3/7 | 2/10 |
| ChillsGeneral disorders | 1/4 | 0/3 | 1/7 | 0/3 | 1/8 | 0/4 | 0/3 | 0/4 | 2/6 | 0/8 | 0/6 | 0/7 | 1/1 | 1/7 | 0/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/4 | 2/3 | 1/7 | 1/3 | 3/8 | 3/4 | 1/3 | 2/4 | 3/6 | 1/8 | 0/6 | 0/7 | 1/1 | 1/7 | 3/10 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/7 | 0/3 | 0/8 | 0/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 1/1 | 0/7 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/3 | 5/7 | 0/3 | 5/8 | 0/4 | 3/3 | 3/4 | 4/6 | 4/8 | 0/6 | 3/7 | 1/1 | 5/7 | 5/10 |
| Eye painEye disorders | 0/4 | 0/3 | 0/7 | 0/3 | 0/8 | 1/4 | 0/3 | 0/4 | 0/6 | 0/8 | 0/6 | 0/7 | 1/1 | 0/7 | 0/10 |
Safety population, all participants who received any amount of MLN2480.
| Age, Continuous(years) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 57.5 (48 to 61) | 48.0 (37 to 63) | 60.9 (24 to 77) | 51.0 (30 to 64) | 68.0 (59 to 77) | 66.0 (54 to 74) | 60.3 (57 to 65) | 70.0 (62 to 78) | 54.2 (41 to 67) | 65.9 (46 to 77) | 52.8 (37 to 66) | 60.1 (48 to 70) | 62.0 (62 to 62) | 62.3 (46 to 75) | 63.9 (57 to 75) | 62.3 (24 to 78) |
| Sex: Female, Male(Participants) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 1 | 6 | 2 | 2 | 3 | 5 | 4 | 2 | 4 | 0 | 3 | 5 | 47 |
| Male | 1 | 0 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 3 | 1 | 4 | 5 | 34 |
| Ethnicity (NIH/OMB)(Participants) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 4 | 3 | 7 | 0 | 8 | 3 | 1 | 4 | 5 | 7 | 5 | 4 | 1 | 7 | 6 | 65 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 3 | 0 | 0 | 4 | 14 |
| Race/Ethnicity, Customized(Participants) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 4 | 3 | 6 | 1 | 8 | 4 | 2 | 4 | 3 | 6 | 6 | 4 | 1 | 7 | 5 | 64 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Not Reported | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 0 | 0 | 4 | 12 |
| Height(centimetres (cm)) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 168.9 (158 to 191) | 163.4 (158 to 173) | 166.7 (156 to 175) | 160.3 (158 to 163) | 164.5 (158 to 171) | 167.0 (155 to 178) | 167.7 (161 to 175) | 166.3 (161 to 176) | 159.7 (152 to 168) | 167.3 (147 to 183) | 169.8 (159 to 180) | 167.4 (147 to 180) | 182.5 (182.5 to 182.5) | 172.3 (161 to 182) | 162.7 (154 to 173) | 164.7 (147 to 191) |
| Weight(kilograms (kg)) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 71.55 (49.5 to 111.8) | 80.53 (68.1 to 96.1) | 84.62 (56.5 to 137.6) | 74.15 (71.0 to 77.3) | 63.59 (44.0 to 79.5) | 86.63 (82.9 to 95.5) | 77.40 (60.1 to 109.1) | 65.45 (48.0 to 81.8) | 67.92 (53.2 to 92.0) | 65.79 (44.7 to 99.0) | 76.22 (55.9 to 90.0) | 71.39 (50.0 to 99.0) | 86.50 (86.5 to 86.5) | 74.97 (60.4 to 95.0) | 67.65 (40.0 to 91.9) | 70.31 (40.0 to 137.6) |
| Body Surface Area (BSA)(square meters (m^2)) | MLN2480 100 mg + MLN0128 2 mg | MLN2480 100 mg + Alisertib 30 mg | MLN2480 160 mg + Alisertib 30 mg | MLN2480 200 mg + Alisertib 30 mg | MLN2480 100 mg + Alisertib 40 mg | MLN2480 100 mg + Paclitaxel 80 mg/m^2 | MLN2480 160 mg + Paclitaxel 80 mg/m^2 | MLN2480 200 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Paclitaxel 80 mg/m^2 | MLN2480 600 mg + Paclitaxel 80 mg/m^2 | MLN2480 400 mg + Cetuximab 250 mg/m^2 | MLN2480 600 mg + Cetuximab 250 mg/m^2 | ML2480 300 mg + Irinotecan 180 mg/m^2 | ML2480 400 mg + Irinotecan 180 mg/m^2 | Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.818 (1.50 to 2.43) | 1.906 (1.74 to 2.05) | 1.961 (1.59 to 2.57) | 1.817 (1.77 to 1.87) | 1.698 (1.41 to 1.91) | 2.003 (1.89 to 2.12) | 1.884 (1.67 to 2.30) | 1.732 (1.47 to 2.00) | 1.726 (1.51 to 2.01) | 1.738 (1.37 to 2.22) | 1.893 (1.61 to 2.12) | 1.814 (1.43 to 2.22) | 2.094 (2.094 to 2.094) | 1.925 (1.69 to 2.19) | 1.740 (1.31 to 2.06) | 1.846 (1.31 to 2.57) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jan 2015 to primary completion in Jul 2018, 41 months.
Results were first posted in Feb 2020, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tovorafenib
Millennium Pharmaceuticals, Inc. →